Shares of Braveheart Investment Group plc (LON: BRH) soared on Friday after the investment company announced that one of its investee companies Paraytec had completed the proof of concept for a COVID-19 test.
Braveheart noted the proof of concept has now been attained for the capture and signal generation modules, thereby successfully completing the proof of concept trials for the test.
The company will now focus on the acquisition of clinically relevant data to facilitate optimisation of the functional capabilities of the test, together with a programme of product refinement and development.
WELCOME BONUS - Free Share Bundle When You Invest £50!
Open a UK Investment Account: Shares, ISAs, Managed Portfolio
Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.
IG
View Offers
Empfohlener Broker
Multi Asset Platform
The firm is currently talking to regulators to get approval for live virus trials and the acquisition of clinical data.
Trevor Brown, Braveheart’s CEO said: “This is a phenomenal achievement for all concerned. The inspirational leadership and innovative brilliance of Professor Carl Smythe and his talented team have resulted in proof of concept in a little over four months.”
Braveheart share price
Braveheart shares ended Friday’s session up 25% on the news.
People who read this also read:
- Our latest trending stories
- Trade shares with the highly-rated IG
- Here are the 7 best shares to buy in 2020